Skip to main content
. 2024 Jun 24;15(6):446. doi: 10.1038/s41419-024-06844-x

Fig. 4. UBE3B alleviates VHL’s inhibitory effect on breast tumor growth and metastasis.

Fig. 4

A–C Tumor images (A), tumor growth curves (B), and tumor weight (C) of mice with orthotopic implantation of EV (empty vector), Flag-VHL, and Flag-VHL + Myc-UBE3B MDA-MB-231 cells into the mammary fat pad (mean ± SD, n = 4). ****P < 0.0001, by 2-way ANOVA Tukey’s multiple comparisons test (B) or 1-way ANOVA Tukey’s multiple comparisons test (C). D–G Representative H&E staining and immunohistochemical staining of Ki-67, CC3 (cleaved caspase-3), and endomucin in primary tumors (D). Scale bars: 100 μm. Ki-67-positive cell numbers (E), CC3-positive cell numbers (F), and microvessel density (G) were quantified. (mean ± SD, n = 4). ***P < 0.001, ****P < 0.0001, by 1-way ANOVA Dunnett’s multiple comparisons test. H, I Representative images of metastases and protein levels of UBE3B and VHL in the lungs analyzed by H&E staining and IHC staining (H), respectively. Lung metastases were quantified by qPCR (H) (mean ± SD, n = 4). **P < 0.01, ***P < 0.001, ****P < 0.0001, by 1-way ANOVA Tukey’s multiple comparisons test. Scale bars: 500 μm.